1. Home
  2. TMC vs ZYME Comparison

TMC vs ZYME Comparison

Compare TMC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TMC the metals company Inc.

TMC

TMC the metals company Inc.

N/A

Current Price

$3.76

Market Cap

2.1B

ML Signal

N/A

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

N/A

Current Price

$25.96

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TMC
ZYME
Founded
2011
2003
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
TMC
ZYME
Price
$3.76
$25.96
Analyst Decision
Buy
Strong Buy
Analyst Count
6
13
Target Price
$10.90
★ $41.23
AVG Volume (30 Days)
★ 3.9M
494.2K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 232.00
33.33
EPS
★ 0.19
N/A
Revenue
N/A
★ $105,965,000.00
Revenue This Year
N/A
$186.92
Revenue Next Year
N/A
$16.24
P/E Ratio
$20.16
★ N/A
Revenue Growth
N/A
★ 38.87
52 Week Low
$3.40
$16.00
52 Week High
$11.35
$31.34

Technical Indicators

Market Signals
Indicator
TMC
ZYME
Relative Strength Index (RSI) 41.29 47.17
Support Level $3.54 $22.10
Resistance Level $4.81 $27.30
Average True Range (ATR) 0.20 1.09
MACD -0.02 -0.14
Stochastic Oscillator 19.35 33.08

Price Performance

Historical Comparison
TMC
ZYME

About TMC TMC the metals company Inc.

TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: